ArticleJournal of inflammation research2025
The Efficacy of Combined Lamotrigine and Levetiracetam Therapy in Epileptic Patients and Its Effects on Hippocampal Volume and Neuroinflammatory Response.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the efficacy of combined lamotrigine and levetiracetam therapy in epileptic patients and its impact on hippocampal volume and inflammatory response. Methods: A retrospective analysis was conducted on the clinical data of 120 epileptic patients admitted to our hospital from December 2022 to February 2024. All patients met the inclusion and exclusion criteria. Based on the treatment received, patients were divided into a control group (n=60, treated with lamotrigine) and an observation group (n=60, treated with lamotrigine combined with levetiracetam). Clinical efficacy, bilateral hippocampal volume, inflammatory factors, brain injury markers, and adverse reactions were compared between the two groups. Results: ① Clinical efficacy: The observation group had higher effective rates in seizure control and EEG epileptiform discharge improvement than the control group (P<0.05). ② Hippocampal volume: No significant differences were observed in bilateral hippocampal volume changes between the two groups before and after treatment (P>0.05). ③ Inflammatory factors: TNF-α, hs-CRP, and IL-6 levels decreased in both groups after treatment, with greater reductions in the observation group (P<0.05). ④ Brain injury markers: S-100β and HMGB-1 levels decreased in both groups after treatment, with greater reductions in the observation group (P<0.05). ⑤ Adverse reactions: The incidence of adverse reactions was comparable between the two groups (P>0.05). Conclusion: Compared with lamotrigine monotherapy, lamotrigine combined with levetiracetam further improves treatment efficacy in epileptic patients, reduces inflammatory response and brain injury, and does not increase the risk of adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.